Ribosome Inactivating Proteins from Plants: Biological Properties and their Use in Experimental Therapy
Ribosome-inactivating proteins (RIPs) are 28 S rRNA N-glycosidases isolated mainly from plants that irreversibly inactivate ribosomes, thereby impairing protein synthesis. In recent years, polynucleotide:adenosine N-glycosidase activity and induction of apoptosis have been reported and may have a particular significance. There are two classes of RIPs: type 1 RIPs, consisting of single-chain proteins, and type 2 RIPs, consisting of an A chain with RIP properties covalently linked to a B chain with lectin properties. Type 2 RIPs may be very toxic or non toxic, whereas type 1 RIPs are always non-toxic. Due to the diverse activities of RIPs, research has been conducted to investigate their use as antiviral and antitumor agents or as the toxic part of conjugates. Conjugates consist of a targeting portion such as an antibody, a lectin or a growth factor linked to a toxic portion. RIPs have been used as the toxic portion in conjugates that have been tested in several experimental therapies against various malignancies. Although some important disadvantages still need to be improved, recent clinical trials encourage the use of these conjugates as efficacious agents in the treatment of cancer and other diseases.
KeywordsProtein Synthesis Inhibition Oral Squamous Cell Carcinoma Cell Disulphide Bridge Vascular Leak Syndrome Sugar Binding Site
This work was supported by grants FISPI04/1279 to J.M.F. and BIO39/VA42/10 to L.C. We thank Judy Callaghan (Monash University, Melbourne, Australia) for correcting the manuscript.
- 8.Ferreras JM, Citores L, Iglesias R, Jiménez P, Girbés T (2010) Sambucus ribosome-inactivating proteins and lectins. In: Lord JM, Hartley MR (eds) Toxic plant proteins-series plant cell monographs, vol 18. Springer, Berlin, pp 107–131Google Scholar
- 17.Sikriwal D, Batra JK (2010) Ribosome inactivating proteins and apoptosis. In: Lord JM, Hartley MR (eds) Toxic plant proteins-series plant cell monographs, vol 18. Springer, Berlin pp 167–189Google Scholar
- 41.Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG (2012) Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 11:143–153PubMedCrossRefGoogle Scholar